Here are four takeaways:
1. AlloSource is a provider of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care.
2. Under the agreement, Integra gains access to acellular dermal matrices derived from donated human dermis along with rights to market these matrices.
3. In particular, Integra’s new product line, marketed under the name HuMend Acellular Dermal Matrix, will allow Integra to offer soft tissue repair solutions for patients undergoing plastic reconstructive procedures.
4. Integra expects to launch HuMend in mid-2016.
More articles on devices:
Lattice Biologics to launch three MAR products — 3 highlights
Bone Biologics completes $5M+ financing round: 3 things to know
RTI Surgical launches laminoplasty fixation system: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
